Clinical Trials

2 studies in Gastroparesis

1. A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus) Rochester, MN View Summary
   Close

   A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Heme oxygenase 1 (HO-1) is an enzyme which protects cells from physical, chemical, and biologic stress. In mice with diabetes and slow gastric emptying, hemin increases HO-1 activity and improves gastric emptying. Hemin is produced from red blood cells and is approved by the Food and Drug Administration for treating acute porphyria, which is an inherited condition caused by an enzyme deficiency. Hemin is not approved by the Food and Drug Administration for treating gastroparesis.

   NCT ID:

   NCT01206582

   IRB Number:

   09-000129

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Shannon L Thieke 507-538-3883
                       
   
   
   

2. Endoscopic Full Thickness Biopsy, Gastric Wall. Rochester, MN View Summary
   Close

   Endoscopic Full Thickness Biopsy, Gastric Wall.

   Location:

   Rochester, MN

   Trial status:

   Open for Enrollment

   Why is this study being done?

   Our group has studied a new endoscopic method using a submucosal endoscopy with mucosal flap (SEMF) technique to acquire full thickness gastric tissues successfully and safely in preclinical studies. The proposed study will assess the efficacy and safety of the innovative endoscopic technique for the acquisition of full thickness gastric muscle wall biopsies. Having access to full thickness biopsies will allow an increased understanding of the pathophysiology of gastrointestinal diseases such as functional gastrointestinal disorders, gastroparesis, pseudoobstruction and other motility disorders. This information is essential to development of more targeted and effective therapy than currently available. Despite the high prevalence of functional gastrointestinal disorders and its significant impact on social and health care costs, the underlying cause is not well understood and there is no effective specific treatment to successfully alleviate patient symptoms.

   NCT ID:

   NCT01650714

   IRB Number:

   12-000714

   • Print Summary
   • View study details

   Who can I contact for additional information about this study?

   Rochester: Elizabeth Rajan, MD 507-266-3972
                       Mary A Knipschield 507-266-3972